💊 Sotalol

Sotalol is a unique antiarrhythmic agent classified as a Class III antiarrhythmic, but it also possesses significant non-selective beta-blocking (Class II) properties. It is often referred to as a 'beta-blocker with Class III activity'.

Sotalol prolongs the cardiac action potential and refractory period by blocking potassium channels (Class III effect), similar to amiodarone. Additionally, it non-selectively blocks beta-adrenergic receptors (Class II effect), leading to a reduction in heart rate and myocardial contractility. These combined actions contribute to its antiarrhythmic efficacy.

Sotalol is used for the treatment of various supraventricular and ventricular arrhythmias. Key indications include the maintenance of sinus rhythm in patients with symptomatic atrial fibrillation or flutter, and the treatment of life-threatening ventricular tachyarrhythmias. It is often considered for patients where a beta-blocker is also indicated.

Absolute contraindications include significant bradycardia, sick sinus syndrome, second- or third-degree AV block (unless a pacemaker is in situ), uncontrolled heart failure, cardiogenic shock, and severe asthma or COPD. Known hypersensitivity to sotalol, prolonged QT interval, and hypokalaemia or hypomagnesaemia are also contraindications due to the risk of Torsades de Pointes.

Common adverse effects are related to its beta-blocking activity and include fatigue, bradycardia, dizziness, and cold extremities. More serious adverse effects include proarrhythmia, particularly Torsades de Pointes, which is dose-dependent and increased by hypokalaemia/hypomagnesaemia. It can also exacerbate heart failure, cause bronchospasm, and lead to hypotension.

Baseline and regular ECGs are essential to monitor for QT interval prolongation and bradycardia. Electrolytes, particularly potassium and magnesium, must be checked and corrected before and during treatment, as imbalances increase the risk of Torsades de Pointes. Renal function should be monitored as sotalol is primarily renally excreted.

Always confirm patient allergies and review for contraindications such as asthma, heart failure, or pre-existing QT prolongation. Be aware of interactions with other QT-prolonging drugs, and drugs that can cause hypokalaemia (e.g., diuretics). Counsel patients about potential side effects like dizziness and fatigue, and the importance of reporting any new symptoms like fainting or severe palpitations.

Sotalol's unique combination of beta-blockade and potassium channel blockade makes it effective for both rate and rhythm control. The risk of Torsades de Pointes is a major concern, necessitating careful patient selection, electrolyte correction, and ECG monitoring for QT prolongation. It is generally avoided in patients with structural heart disease due to increased risk of proarrhythmia, similar to Class Ic agents.

SBA questions often focus on the dual Class II and Class III properties of sotalol and the significant risk of Torsades de Pointes, especially with hypokalaemia or prolonged QT. They might also test its contraindications, particularly in asthma or heart failure. Differentiating its use from other antiarrhythmics based on patient comorbidities is a common theme.